Skip to Content
Merck
All Photos(1)

Key Documents

I5771

Sigma-Aldrich

Interleukin-6 Receptor Soluble Fragment human

recombinant, expressed in Sf21 cells, ≥97% (SDS-PAGE), lyophilized powder

Synonym(s):

IL-6 sR

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
51111800
NACRES:
NA.41

recombinant

expressed in Sf21 cells

Quality Level

Assay

≥97% (SDS-PAGE)

form

lyophilized powder

impurities

endotoxin, tested

storage temp.

−20°C

General description

Interleukin-6 is a pleotropic cytokine involved in hematopoiesis, inflammation and immune response. IL-6 is secreted by macrophages, dendritic cells and B cells, in response to TNF-α, PGDF and IL-1. The signaling by IL-6 is mediated by heterodimeric receptor, IL-6R, comprising of IL-6Rα (soluble factor) and gp130 (sometimes called IL-6Rβ). Gp130 is crucial component for downstream signal transduction. In response to IL-6, gp130 activates kinases of JAK family, STATs, MAPK and Ras proteins. IL-6R-mediated signaling is essential for normal development of T and B cells and has been implicated in many diseases such as rheumatoid arthritis, Crohn disease, sepsis, fever, systemic lupus erythematosus, osteoporosis and insulin resistance
Interleukin-6 Receptor soluble fragment specifically binds and inhibits the activity of human IL-6 in free form or when bound to cell surface receptors.

Application

Interleukin-6 Receptor soluble fragment elicits a 50% increase in IL-6 activity in cell based assay at a concentration (EC50) of 1-10 ng/ml.

Physical form

Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing 1.25 mg bovine serum albumin.

Analysis Note

The receptor mediated activity of human IL-6 receptor soluble fragment is measured by its ability to increase the IL-6 inhibition of M1 cells.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

David S Hong et al.
Cancer, 110(9), 1911-1928 (2007-09-13)
Interleukin-6 (IL-6) plays a major role in the response to injury or infection and is involved in the immune response, inflammation, and hematopoiesis. Its deregulation impacts numerous disease states, including many types of cancer. Consequently, modulating IL-6 may be an
Interleukin-6-type cytokines.
P B Sehgal et al.
Annals of the New York Academy of Sciences, 762, 1-14 (1995-07-21)
T Gustot et al.
Gut, 54(4), 488-495 (2005-03-09)
Soluble cytokine receptors (sCRs) modulate the in vivo activity of cytokines. Deficient sCR production could participate in the pathogenesis and course of Crohn's disease (CD). The aim of the study was to examine the profile of sCRs in CD patients
T Saito et al.
Journal of immunology (Baltimore, Md. : 1950), 147(1), 168-173 (1991-07-01)
Starting with a previously isolated cDNA clone encoding murine IL-6R, a stable transformed Chinese hamster ovary cell line constitutively expressing soluble murine IL-6R (smIL-6R) has been established. The smIL-6R was purified to homogeneity by sequential filtration and chromatography of culture
T van der Poll et al.
Infectious disease clinics of North America, 13(2), 413-426 (1999-05-26)
Clinical trials with anti-inflammatory agents in patients with sepsis are based on the assumption that excessive proinflammatory activity of the cytokine network negatively influences the outcome of severe bacterial infections. The failure of these trials to show clinical benefit, in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service